Definium Therapeutics, Inc. filings document the regulatory record of a British Columbia clinical-stage biopharmaceutical company traded on Nasdaq as DFTX. Current reports on Form 8-K disclose financial results, corporate highlights, investor-presentation materials, and clinical and commercial updates for DT120 ODT in psychiatric indications.
Definitive proxy materials cover annual general and special meeting matters, including director elections, auditor appointment, compensation governance, and shareholder voting procedures. Other filings record board composition changes, non-employee director compensation, stock option awards, indemnity arrangements, and the company’s corporate identity following its former name, Mind Medicine (MindMed) Inc.
Definium Therapeutics, Inc. Chief Medical Officer Daniel Karlin sold 10,853 Common Shares on September 25, 2026, at a weighted average price of $36.57 per share. The sale satisfied withholding tax obligations connected with settlement of vested restricted stock units under sell-to-cover elections pursuant to a Rule 10b5-1 plan adopted June 15, 2022. The reported prices ranged from $36.24 to $36.98, and Karlin directly held 792,846 shares after the sale.
Definium Therapeutics, Inc. CEO Robert Barrow sold 31,550 Common Shares on September 25, 2026, at a weighted average price of $36.57 per share. The shares were sold through sell-to-cover elections to meet withholding tax obligations on vested restricted stock units under a Rule 10b5-1 plan adopted June 15, 2022. Prices ranged from $36.24 to $36.98 across the transactions. Barrow directly held 2,213,090 shares following the sale.
Definium Therapeutics, Inc. Chief Commercial Officer Matthew T. Wiley sold 3,097 common shares on September 25, 2026, through sell-to-cover elections for withholding taxes on vested restricted stock units. The sale was under a Rule 10b5-1 plan adopted on May 29, 2025. The weighted average sale price was $36.57 per share, with transactions ranging from $36.24 to $36.98. Wiley directly held 359,036 shares after the sale.
Definium Therapeutics, Inc. Chief Legal Officer Mark Sullivan sold 14,051 Common Shares on September 25, 2026, at a weighted average price of $36.57 per share. The shares were sold to satisfy withholding tax obligations connected with settlement of vested restricted stock units, through sell-to-cover elections under a Rule 10b5-1 plan adopted on March 14, 2024. Prices across the transactions ranged from $36.24 to $36.98. Sullivan reported direct holdings of 494,228 Common Shares after the sale.
Definium Therapeutics, Inc. Chief Financial Officer Brandi Roberts reported selling 3,377 Common Shares on September 25, 2026, to satisfy withholding tax obligations related to vested restricted stock units. The shares were sold through sell-to-cover elections under a Rule 10b5-1 plan adopted May 30, 2025.
The reported weighted average sales price was $36.57 per share; individual sales ranged from $36.24 to $36.98. Roberts reported holding 394,528 shares after the transaction.
A Form 144 notice concerning Definium Therapeutics, Inc. (DFTX) lists officer Mark Sullivan's proposed sale of 14,051 common shares, with an approximate sale date of September 25, 2026 and an aggregate market value of $516,093.23. Morgan Stanley Smith Barney LLC is named as broker. The securities are described as restricted stock vesting under a registered plan.
Definium Therapeutics, Inc. (DFTX) officer Brandi Roberts reported a proposed sale of 3,377 common shares on September 25, 2026, with an aggregate market value of $124,037.21. The notice lists 134,367,000 shares outstanding and names Morgan Stanley Smith Barney LLC as broker. It also reports that Roberts sold 3,013 common shares on June 25, 2026, with an aggregate market value of $126,937.69.
Definium Therapeutics, Inc. (DFTX) lists 3,097 common shares for sale by Officer Matthew Thomas Wiley, with an approximate sale date of September 25, 2026, and an aggregate market value of $113,752.81. The notice attributes the shares to restricted stock vesting under a registered plan. It also lists 2,867 common shares sold during the prior three months, with an aggregate market value of $120,786.71.
Definium Therapeutics, Inc. officer Daniel Rollings Karlin reported a proposed sale of 10,853 common shares, with an aggregate market value of $398,630.69 and an approximate sale date of September 25, 2026. The shares are listed as restricted stock vesting under a registered plan, acquired from the issuer for services rendered. Karlin reported selling 10,035 common shares on June 25, 2026, for $422,774.55 during the prior three months.
Definium Therapeutics, Inc. reports that Robert B. Barrow, identified as an officer and director, gave notice of a proposed sale of 31,550 common shares through Morgan Stanley Smith Barney LLC, with an approximate sale date of September 25, 2026, on NASDAQ. The notice lists an aggregate market value of $1,158,831.50 and identifies the shares as restricted stock vesting under a registered plan for services rendered. It also lists earlier sales by Barrow of 19,023 shares for $718,144.88 on September 3, 2026, and 29,208 shares for $1,230,533.04 on June 25, 2026.